RBC Capital analyst Gregory Renza raised the firm’s price target on Ideaya Biosciences (IDYA) to $38 from $36 and keeps an Outperform rating on the shares after the company presented updates across their clinical and preclinical portfolio at an R&D Day. The firm continues to think there is significant long-term upside across Ideaya pipeline, and near-term catalysts such as the registrational PFS update for daro/cris in mUM are also likely to be positive, driving share appreciation, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Promising Pipeline and Competitive Edge: IDEAYA Biosciences Receives Buy Rating from Analyst
- Ideaya should be bought on yesterday’s selloff, says Wells Fargo
- Ideaya Biosciences selloff on R&D day overdone, says Citi
- IDEAYA Biosciences: Promising Pipeline and Clinical Advancements Drive Buy Rating
- Ideaya Biosciences price target lowered to $36 from $37 at Oppenheimer